Poisoning by BenzodiazepinesNCT05184959
Correlation Between Immune Metabolism in Patients With Benzodiazepine Poisoning and Patients'Mental Disorders
An observational study of Poisoning by Benzodiazepines and Depression, run by Second Affiliated Hospital, Zhejiang University, School of Medicine.
Trial summary
High-dose benzodiazepines can inhibit the central nervous system, respiratory system and cardiovascular motor center, resulting in loss of consciousness, disappearance of reflex, respiratory inhibition, decrease of blood pressure and so on. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Poisoning by Benzodiazepines, Depression
- How many people
- 30 participants
- Where
- No sites listed yet
- Study dates
- 1 Feb 2022to 1 Dec 2022
- How long will I take part?
- 1 Month
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: posioning with Benzodiazepine along with at least one organ dysfucntion
Who may be able to join
- Benzodiazepine poisoning Within 6 hours, at least one target organ dysfunction. No bad habits (drug use, alcohol addiction)
Who cannot join
- Refusal to join this study Lack of information/incompleteness Vulnerable groups such as pregnant women, incapable of civil conduct and indeterminate agent consent Chronic multiple organ dysfunction Tumors, blood system diseases, various systemic immune diseases Various infectious diseases (various hepatitis, tuberculosis, AIDS)
About this study
Official title: Correlation Between Early Neuro-immune Metabolism in Patients With Benzodiazepine Poisoning and Mental Disorders With Depression --- A Multiple Center Observational Study
High-dose benzodiazepines can inhibit the central nervous system, respiratory system and cardiovascular motor center, resulting in loss of consciousness, disappearance of reflex, respiratory inhibition, decrease of blood pressure and so on. This kind of drug acute poisoning is the most common drug poisoning in internal medicine. It has acute onset and severe symptoms. If it is not treated properly in time, it can be life-threatening. At present, the research on the accumulation and metabolic state caused by benzodiazepine poisoning is not sufficient; at the same time, the changes of neuroendocrine metabolism and immune function of patients with neuroendocrine metabolism and immune function need to be further explored. Therefore, the main purpose of this study is to analyze the effects of neuroendocrine metabolism and immune function on organ function and mental state in patients with benzodiazepine poisoning.
Read the detailed description
Benzodiazepines are the first choice for clinical anti-anxiety, sedation and hypnosis, as well as anticonvulsant, antiepileptic and central muscle relaxation. Commonly used are diazepam (diazepam), nitro diazepam, clonazepam, alprazolam, triazolam and so on. The drug itself is an inhibitor of the central nervous system, which has a high selectivity for the inhibition of the central nervous system, mainly inhibiting the limbic system of the brain and less inhibitory effect on the reticular ascending activation system. It mainly acts on the synaptic sites of GABA-Ergic nerve endings in the central nervous system. It enhances the affinity between GABA and its receptors by binding to benzodiazepine receptors, thus increasing the open frequency of Cl- channels coupled with GABA receptors and exerting an inhibitory effect. High-dose benzodiazepines can inhibit the central nervous system, respiratory system and cardiovascular motor center, resulting in loss of consciousness, disappearance of reflex, respiratory inhibition, decrease of blood pressure and so on. This kind of drug acute poisoning is the most common drug poisoning in internal medicine. It has acute onset and severe symptoms. If it is not treated properly in time, it can be life-threatening. At present, the research on the accumulation and metabolic state caused by benzodiazepine poisoning is not sufficient; at the same time, the changes of neuroendocrine metabolism and immune function of patients with neuroendocrine metabolism and immune function need to be further explored. Therefore, the main purpose of this study is to analyze the effects of neuroendocrine metabolism and immune function on organ function and mental state in patients with benzodiazepine poisoning.
- Conditions
- Poisoning by Benzodiazepines, Depression
- Keywords
- poisoning, benzodiazepines, neuro-immunity
- Medical subject headings
- Depression, Poisoning
What is being measured
The primary outcome is the main question the study is designed to answer.
Time interval
Interval from benzodiazepine poisoning to emergency pre-examination
Measured: at admittion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jan 2022
- Study start1 Feb 2022 (estimated)
- Primary completion1 Jun 2022 (estimated)
- Study completion1 Dec 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Poisoning by BenzodiazepinesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 30 participants (estimated)
- Target duration
- 1 Month
Sponsor and investigators
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05184959
- Sponsor's protocol ID
- 2021-1069
- Status last verified
- Dec 2021
- First submitted
- 22 Dec 2021
- Last updated
- 11 Jan 2022
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No